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Neutralizing antibodyThe rare, broadly neutralizing antibodies, 4E10 and 2F5, that target the HIV-1 membrane proximal external
region also associate with HIV-1 membrane lipids as part of a required ﬁrst-step in HIV-1 neutralization. HIV-1
virions have high concentration of cholesterol and sphingomyelin, which are able to organize into liquid-
ordered domains (i.e., lipid rafts), and could inﬂuence the interaction of neutralizing antibodies with epitopes
proximal to the membrane. The objective of this research is to understand how these lipid domains contribute
to 2F5/4E10 membrane interactions and to antigen presentation in liposomal form of HIV-1 vaccines. To this
end we have engineered biomimetic supported lipid bilayers and are able to use atomic force microscopy to vi-
sualize membrane domains, antigen clustering, and antibody–membrane interactions. Our results demonstrate
that 2F5/4E10 do not interact with highly ordered gel and liquid-ordered domains and exclusively bind to a
liquid-disordered lipid phase. This suggests that vaccine liposomes that contain key viralmembrane components,
such as high cholesterol content, may not be advantageous for 2F5/4E10 vaccine strategies. Rather, vaccine lipo-
somes that primarily contain a liquid-disordered phase may be more likely to elicit production of lipid reactive,
2F5- and 4E10-like antibodies.cal Engineering and Materials
United States. Tel.: +1 919 660© 2014 Elsevier B.V. All rights reserved.1. Introduction
Induction of broadly neutralizing antibodies (NAbs) against HIV-1
remains an exceptional challenge. However, several, rare antibodies
have been isolated that are broadly neutralizing, including monoclonal
antibodies, 2F5 and 4E10. The neutralizing mechanism of 2F5/4E10 rep-
resents a promising framework for the design of new HIV-1 liposomal
vaccines. In-vitro studies have shown that 2F5/4E10 successfully inhibit
the fusion process of HIV-1 by binding themembrane-proximal external
region (MPER) of viral gp41 via a two-stage mechanism: NAbs 2F5 and
4E10 ﬁrst interact nonspeciﬁcally with the viral lipid membrane and
then with the target MPER [1,2]. Induction of polyreactive antibodies
that can bind to both, lipids and antigen is thus required for MPER-
targeted HIV-1 neutralization. Understanding the role of the lipid mem-
brane in 2F5/4E10's neutralizationmechanism can help select importantlipid components to be used in the synthesis of vaccine liposomes. We
posit that vaccine liposomes that contain the MPER antigen in an lipid
environment optimized for 2F5 and 4E10 interactions are more likely
to induce the desired, polyreactive NAbs. The research results presented
here provide information on lipid selection when developing new im-
munogen designs against HIV-1.
The interaction between lipids and 2F5/4E10 is likely mediated by
the NAb's unique complementary determining region (CDR) H3 loop
[3]. The CDR H3 regions contain an unusually large number of hydro-
phobic and membrane-reactive residues, suggesting that they can
embed in the viral membrane and position the NAb to encounter and
bind its antigen [4,5]. Mutations in these CDR H3 antibody regions
allow 2F5/4E10 to bind MPER's linear and conformational epitopes,
but prevent the NAb's lipid reactivity, which results in the inability
to bind membrane bound MPER antigen [6]. This phenomenon may
explain why simple peptide immunogens that mimic neutralizing epi-
topes on gp41 do not elicit NAbs in vivo, [7] and it is clear that antigen
sequence is not the sole determinant of neutralizing ability. To mimic
2F5 and 4E10's in-vitro neutralizing ability, in-vivo immunogens must
elicit antibodies that also react with the HIV-1 lipid envelope. How to
design immunogens to do this remains largely unknown.
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It is currently believed that the viral envelope contains highly or-
dered lipid domains (i.e., lipid rafts) and that these lipid domains inﬂu-
ence lipid–NAb interactions. Generally, lipid domains are deﬁned as
areas of a membrane that have a different composition from their sur-
roundings, i.e., an enrichment or depletion of certainmembrane compo-
nents. The presence of lipid domains indicates lipid phase separation.
There are two main phase types: a solid and a liquid phase. The solid
or “gel” phase is characterized by highly ordered, tightly packed lipids
that, compared with the liquid phase, have limited lateral mobility
(Fig. 1B). The liquid phase can be further divided into the liquid-
disordered (Ld) and liquid-ordered (Lo) phases (Fig. 1C). The Ld phase
exists when lipids have melted from the gel to liquid phase (deﬁned
by the transition temperature, Tm) while the Lo typically forms when
cholesterol (CH) and/or sphingomyelin (SM) exist in Ld membranes.
CH and SM will co-localize within the Ld phase resulting in highly
ordered, tightly packed islands known as Lo domains or lipid rafts [8].
The HIV-1 membrane envelope contains a unique lipid composition
that differs from that of host cell membranes [9] because HIV-1 acquires
its envelope by budding from isolated islands of membrane lipids
enriched in CH and SM [10]. Due to the high concentration of CH and
SM in the native HIV-1 envelope, the Lo domain is expected to dominate
HIV-1 domain structures. Yet, the size, physical properties, and dynam-
ics of such lipid domains are poorly characterized for the HIV-1 enve-
lope, and it is as of yet unknown how lipid domains contribute to 2F5/
4E10-membrane interactions and MPER antigen presentation.Fig. 1. Schematic representation of NAbs, antigen, and lipid organization in SLBs. (A) Proposed S
only interact with the Ld phase (blue) and avoid Lo and gel domains (represented collectively in
surrounded by Ld phase (light green). (C) Lipid organization expected from themodel HIV SLB.
green).1.2. Supported lipid bilayer model membrane platform
To help understand how lipid domains inﬂuence NAb- and antigen-
membrane interactionswe have created supported lipid bilayers (SLBs)
that can phase separate spontaneously into stable lipid domain struc-
tures (Fig. 1). Because SLBs can recapitulate the lateral lipid diffusivity
of native cellmembranes and are stable and conﬁned in twodimensions
to the substrate surface, they can be used to model the composition,
organization, and properties of native lipid bilayers [11].
Although several spectroscopy-based techniques have been used to
help understand the role of lipids in 2F5/4E10 HIV-1 neutralization and
vaccine design, [12,13] these techniques lack high lateral resolution
and cannot visualize how membrane morphology, such as lipid do-
mains, contribute to NAb- and antigen-membrane interactions. To visu-
alize NAb- and antigen-membrane interactions, we used atomic force
microscopy (AFM) [14] to produce high-resolution, topographical
images of three different SLBs: an Ld SLB, an Ld–gel SLB, and an Ld–Lo
SLB made from a complex, ﬁve-component lipid mixture that mimics
the lipid composition of the native HIV-1 envelope.
Unlike many surface-sensitive, spectroscopy techniques, AFM can
visualize how antibodies and antigens spatially interact with lipid do-
mains. We show that AFM reveals the height mismatch between lipid
domains and surface-associated proteinswith Ångstromvertical resolu-
tion and approximately 5–10 nm lateral resolution. By visualizing these
interactions,weprovide important information for thedesign of vaccine
liposomes that optimize membrane-dependent antibody binding and
antigen presentation.LB environment interacting with NAbs (green) andMPER656 (yellow). NAbs andMPER656
red). (B) Lipid organization expected from the POPC:POPE SLB. Gel domain (dark green)
Lo domains consisting of sphingomyelin (red) and cholesterol (yellow) in a Ld phase (light
Table 1
Average percent surface coverage (± standard error of themean) NAb binding for all SLBs
tested (calculated from AFM topographical images). (–) Indicates NAb coverage was
undetermined.
SLB 2F5 coverage
(%, n = 3)
4E10 coverage
(%, n = 3)
Ld area Total area Ld area Total area
POPC 3 ± 0 3 ± 0 3 ± 0 3 ± 0
POPC:MPER 42 ± 6 42 ± 6 47 ± 5 47 ± 5
POPC:POPE 3 ± 1 1 ± 0 3 ± 0 1 ± 0
POPC:POPE:MPER 26 ± 7 10 ± 3 19 ± 2 8 ± 1
Model HIV – 4 ± 1 – 2 ± 0
Model HIV:MPER – 2 ± 1 – 2 ± 0
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2.1. Antibody and antigen interactions with Ld SLBs
AFM height images of 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC) SLBs are shown in Figs. 2A–D. In these,
and all following AFM height images, increasing topographical feature
heights are represented by increasing brightness. The POPC SLB appears
smooth,with noobservable height differences in themembrane organi-
zation (Fig. 2A). This smooth topography reﬂects the presence of a
homogenous lipid phase with no observable domain formation.
Since the Tm of POPC is−2 °C, the SLB exists in the Ld phase at room
temperature.
2F5 and 4E10 were each separately added to the POPC SLBs. After
NAb addition, the AFM height images (Figs. 2B,C) reveal bright spots
(i.e., topographical peaks) over the entire membrane surface; we attri-
bute these peaks to the presence of NAbs that have interacted with
the top leaﬂet of the SLB. The surface-associated NAbs cover approxi-
mately 3% of the SLB surface (Table 1). Based on topographical feature
size distributions, the surface-associated NAbs are distributed between
0.5–1.5 nm above the SLB with few feature counts at 2 nm and greater.
Features exceeding 2 nm in height likely reﬂect clusters of antibodies
bound to the SLB. In solution, antibodies such as 2F5 and 4E10 have a
radius of gyration of approximately 7 nm [15]. The small heights of
the topographic peaks suggest that in most instances individual anti-
bodies are bound to the SLB surface. We attribute the apparent size
difference (i.e., height of NAbs on the SLB surface vs. Ab size in solution)
to the tapping force exerted by the AFM cantilever during imaging. ThisFig. 2.AFMheight images of the POPC and POPC:MPER656 SLBs with andwithout antibody addi
(B–D) 2F5, 4E10 and 13H11 added to the POPC SLB, respectively. (E) POPC:MPER656 SLB. (F–Hforce compresses the antibody against and possibly into the SLB, which
results in the smaller observed heights.
MPER656 consists of an amphipathic GTH1 membrane anchor tag
and the binding epitope for both 2F5 and 4E10 [16].While the GTH1 an-
chor resides within the hydrophobic core of the SLB, the NAb binding
epitopes are likely positioned parallel with the top lipid leaﬂet, i.e., at
the interface of the lipid bilayer and bulk solution [17]. Based on the
size of theMPER binding epitope (3.3 kDa), the folded length is approx-
imately 2 nm. When MPER656 is included in the POPC SLB (Fig. 2E),
0.5 nm high topographical peaks appear evenly distributed over the
SLB surface. This subtle, antigen-induced height difference between
the POPC and POPC:MPER656 SLB is further conﬁrmed by the root
mean squared (RMS) surface roughness. Over a 1 μm2 area, the RMS
roughness of the POPC:MPER656 SLB is 2.7 ± 0.2 Å, while that of
the neat POPC bilayer is signiﬁcantly smaller, with 1.6 ± 0.05 Å. Thistion (imaged in liquid at 24 °C). Height cross-section given for select images. (A) POPC SLB.
) 2F5, 4E10, and 13H11 added to the POPC:MPER656 SLB, respectively.
2665G.J. Hardy et al. / Biochimica et Biophysica Acta 1838 (2014) 2662–2669difference in SLB surface roughness can also be seen by comparing
the height cross-sections from Fig. 2A and E, presented below the
topography images.
When NAbs are incubated on these SLB surfaces, they bind preferen-
tially to regions that contain MPER656 antigen (Fig. 2F,G). NAb binding
to the SLB and to MPER656 can be seen by the appearance of “bright
spots”, i.e., peaks 2–4 nm in height, in the SLB height images. The loca-
tions of these peaks are evenly distributed across the SLB surface, sug-
gesting that MPER656 is also evenly distributed. 2F5's surface coverage
is 42 ± 6%, while addition of 4E10 results in a surface coverage of
47 ± 5% (Table 1).
A murine monoclonal antibody, 13H11, was incubated on all SLB
surfaces as control. 13H11 has no lipid reactivity and while it does
bind to the soluble form of the MPER-antigen peptide, it cannot bind
to membrane-embedded MPER [2]. As expected, there is little to no
13H11 interactions with the POPC SLB (Fig. 2D) nor with POPC SLB
containing MPER (Fig. 2H), thus conﬁrming that NAb-membrane inter-
actions are speciﬁc to 2F5 and 4E10.Fig. 3.AFMheight images of the POPC:POPE and POPC:POPE:MPER656 SLBswith andwithout ant
(A) POPC:POPE SLB. The bright area is the taller, gel domain,while the darker area is the lower, L
POPE:MPER656 SLB. Inset: 250 × 250 nmheight image from a replicate sample showingMPER65
from a replicate sample (G) image (F) with a second addition of 2F5 (4.0 μM). (H,I) Repeated c2.2. Antibody and antigen interactions with Ld–Gel SLBs
While NAbs and MPER656 are apparently evenly distributed
throughout the Ld phase of the unary POPC SLB,we next tested their dis-
tribution in a binary, phase-separated SLB, consisting of POPC:1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE) (1:1).
POPC:POPE SLBs, imaged at 18–20 °C (Fig. 3A), revealed a gel domain
consisting of predominantly POPE (Tm = 25 °C) and an Ld phase
consisting of predominantly POPC (Tm=−2 °C). Gel domains are taller
and appear brighter compared to the Ld phase, which is lower and thus
appears darker. The taller POPE gel domains extend 4.8 ± 0.4 Å above
the surrounding POPC Ld phase. When NAbs were incubated on this
phase-separated SLB surface, they interacted only with the Ld phase
(Fig. 3B,C), resulting in a surface coverage on the Ld phase of 3 ± 1%
for 2F5 and 3 ± 0% for 4E10, respectively (Table 1). The tallest NAb
peaks were approximately 1.5 nm above the Ld domain surface.
Next, POPC:POPE:MPER656 SLBs were prepared. AFM images
(Fig. 3E) revealed that MPER656 exclusively localized to the Ld domain.ibody addition (imaged in liquid at 18–20 °C). Height cross-section given for select images.
d phase. (B–D) 2F5, 4E10, and 13H11 added to the POPC:POPE SLB, respectively. (E) POPC:
6 in the Ld phase. (F) 2F5 added to the POPC:POPE:MPER656 SLB. Inset: 250 × 250 nm image
onditions from images (F,G) with 4E10. (M) 13H11 added to POPC:POPE:MPER656 SLB.
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peak widths ranged from about 15 to 30 nm, i.e., much wider than
expected for single MPER656 peptides. This observation suggests that
MPER656 aggregated in the Ld phase.
WhenNAbswere added to the POPC:POPE:MPER656 SLB, they bound
to the SLB and toMPER656, indicated by the presence of 1–2 nmpeaks in
the AFM images (Fig. 3G,I). These images also show that NAbs only
bound to the Ld phase and were excluded from the taller, gel phase.
2F5's Ld surface coverage was 26 ± 1%, while 4E10 addition resulted
in an Ld surface coverage of 19 ± 2% (Table 1). A second addition of
NAbs (4.0 μM) resulted in large clusters (3–7 nm tall) of Ld-localized
NAb (Fig. 3H,J) reaching close to 100% coverage of the Ld phase. No
antibody binding peaks were found in the gel domains, which suggest
that gel domains are either void of MPER656, or the antigen is presented
in a conformation that is not accessible to NAb binding.
As expected, 13H11 showed no interactions with either the POPC:
POPE (Fig. 3D) or the POPC:POPE:MPER656 SLB (Fig. 3F).Fig. 4. AFMheight images of themodel HIV andmodel HIV:MPER656 SLBwith andwithout antib
imaged at 18 °C and 37 °C, respectively. (C,D) 2F5 added to the model HIV SLB at 18 °C and 37
(G) Model HIV:MPER656 SLB at 37 °C. (H–J) 2F5, 4E10, and 13H11 added to the model HIV SLB2.3. Antibody and antigen interactions with model HIV-1 SLBs
A commonSLBmodel of theHIV-1 envelope is a ternary composition
consisting of POPC, SM, and CH [18,19]. Here we use a more physiolog-
ically relevant SLB model of the HIV-1 envelope [20] to study NAb and
antigen interactions. Our model HIV SLB composition consists of POPC,
POPE, 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine (POPS),
brain SM, and CH in a molar ratio of 9.35:19.25:8.25:18.15:45.00. This
composition was previously used to make liposomes for SPR binding
assays in vaccine studies [6,21]. To create SLBswith thismodelHIV com-
position, we have previously developed a vesicle fusion technique that
uses amphipathic, α-helical (AH) peptides as a catalyst to generate
complex SLBs with high cholesterol content [22]. Here, for the ﬁrst
time, we imaged with AFM to visualize NAb and antigen interactions
with this model HIV SLB.
Fig. 4 demonstrates the signiﬁcantmorphological changes that occur
in themodel HIV SLBwhen imaged at 18 °C compared to 37 °C. At 18 °Cody addition. Height cross-section of SLBs given below select images. (A,B) Model HIV SLB
°C, respectively. (E,H) 4E10 and 13H11 added to the model HIV SLB at 37 °C, respectively
:MPER656, respectively (at 37 °C).
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ence of 10.3 ± 0.6 Å between the lowest and medium height domains,
and a height difference of 2.4 ± 0.7 Å between the medium height
and tallest domains. At 37 °C (Fig. 4B), however, only two distinct
phases exist, with a height difference of 8.2 ± 0.4 Å.
Regardless of temperature, the addition of 2F5 resulted in 2F5-
membrane interactions only in the most disordered (i.e., lowest height)
lipid phase (Fig. 4C,D). Tomimic physiological conditions, comprehensive
measurements were conducted on model HIV SLBs at 37 °C. We found
that 2F5 had a surface coverage of 4 ± 1%, and that 4E10 behaved like
2F5, by binding only to themost disordered lipid phase (Fig. 4E), reaching
a surface coverage of 2 ± 0% (Table 1).
When MPER656 was incorporated in the model HIV SLB (37 °C), the
prominent, two-phase SLB no longer existed (Fig. 4G–J). Rather, a more
homogenous lipid phase, with small, about 7 Å deep, narrow depres-
sions appeared in the bilayer (Fig. 4G). We surmise that these depres-
sions consist largely of the Ld phase, likely containing also MPER656.
The surface coverage of these Ld features is 3 ± 0%, i.e., signiﬁcantly
less than the surface coverage of the Ld area on themodel HIV SLBwith-
out antigen (39±3%). Upon addition of NAb, the antibodies only bound
to these depressions (Fig. 4H,I), resulting in a NAb total surface coverage
of 2±1% and 2±0% for 2F5 and 4E10, respectively (Table 1). The taller,
homogenous lipid phase is void of any antigen or antibody binding.
Addition of 13H11 resulted in little to no interactions with the HIV SLB
in absence (Fig. 4F) and presence (Fig. 4J) of MPER656.
Surface plasmon resonance (SPR) experiments (Fig. S1) revealed
that NAb binding was signiﬁcantly higher on the POPC:MPER656 mem-
brane compared with binding on the model HIV:MPER656 membrane
(Figs. S1A,B vs. S1D,E). The Rmax (maximum binding capacity) for
POPC:MPER656 was 65 ± 9 and 214 ± 10 response units (RU) for
4E10 and 2F5, respectively. For the model HIV:MPER656 membrane,
the Rmax dropped to 9 ± 2 RU for 4E10 while binding of 2F5 was even
weaker, and no reliable Rmax values could be determined. These results
qualitatively agree with our surface coverage (i.e., binding) measure-
ments by AFM imaging, which showed NAb coverage to be between
42 and 47% for the POPC:MPER656 SLB compared to only 2 to 4% for
the model HIV:MPER656 SLB. For the POPC and the model HIV mem-
brane, 4E10 resulted in an Rmax of 7 ± 2 and 5 ± 0 RU, respectively,
while 2F5 resulted in an undetectable Rmax. SPRmeasurements showed
no detectable interactions of 13H11 for all membrane compositions
tested (Fig. S1C,F).
3. Discussion
3.1. NAb interactions with SLBs
AFM imaging of NAbs interactingwith the POPC and POPC:POPE SLB
revealed that 2F5 and 4E10 exclusively interacted with the Ld mem-
brane phase. For the POPC SLB the Ld phase made up 100% of the SLB
area, while for the POPC:POPE SLB, the Ld area was 41 ± 4%. Despite
the difference in Ld area, NAb binding coverage was about 3% on both
SLBs. NAb coverage on the Ld area for the model HIV SLB could not be
determined accurately due to the dispersed nature and small size of
the Ld phase. Instead, we report NAb coverage relative to the total area
of the model HIV SLB (Table 1). NAb binding on the model HIV SLB
was similar to that on the POPC and POPC:POPE SLBs. NAbs exclusively
interactedwith the lipid phasewith the lowest height and therefore the
lowest lipid packing density, the largest membrane disorder, and the
highest lipid diffusivity [23–25]. This result is in agreement with a pre-
vious AFM study completed by Franquelim et al. [18]. The lipid diffusiv-
ity in the Lo phase is approximately a factor 2–10 smaller than in the Ld
phase, depending on experimental details [26–28]. The presence of
cholesterol is a major contributor to the physical properties of lipid
domains. It has been shown that the force required to break the inter-
molecular lipid interactions in a cholesterol-rich Lo phase is greater
compared to that in a cholesterol-depleted Ld phase [25]. This supportsthe hypothesis that the high order of Lo and gel domains prevented NAb
insertion into these SLB areas.
Given the overall compositional and structural complexity of the
model HIV SLB, the detailed lipid compositions of individual domains
are unclear, but can be estimated considering the Tm values of the lipids.
At 18 °C, the domain with the lowest height likely contains the highest
concentration of POPC (Tm = −2 °C) and POPS (Tm = 14 °C). The
middle and tallest domains likely contain the highest concentration of
POPE (Tm = 25 °C), SM (Tm = 37 °C), and CH. When the temperature
is increased from 18 °C to 37 °C, the SLB transitions from three to
two phases. This two-phase system is likely a result of CH and SM
redistributing to form discrete Lo–Ld domains. At 37 °C, an Lo–Ld
forming bilayer of the model HIV SLB agrees with the phase diagram
of a similar bilayer composition, i.e., POPC:PSM:CH (1:1:1) [29].
X-ray diffraction experiments of another, similar bilayer composition,
i.e., DOPC:SM:CH (1:1:1), conﬁrm the absence of a gel phase. This sug-
gests that our model SLB also lacks a gel phase, and thus contains a Ld
and Lo phase instead [30]. Furthermore, at 37 °C, ourmodel HIV domain
height difference is 8.2 ± 0.4 Å, which agrees with expected Lo–Ld
height differences. For example, Rinia et al. report similar height differ-
ences observed by AFM for DOPC:SM:CH bilayers that phase separate
into Lo–Ld domains [31]. Thus, we believe that a Ld phase exists in our
model HIV SLB, and that since the Ld phase contains the highest lipid
disorder, it should reside in the domains of lowest SLB height, i.e., the
same domains to which NAbs bind. This suggests that NAbs interact
exclusively with the Ld phase in the model HIV SLB.
Collectively, our experiments on the three SLB systems tested, dem-
onstrate that NAbs 2F5/4E10 bind exclusively to the Ld phase and do not
interact with the ordered gel and Lo domains. This also suggests that
these NAbs likely target Ld regions on the native virus before binding
to their MPER antigen on gp41. To elicit antibodies that can recognize
and interact with the Ld phase, vaccine liposomes likely should
also contain lipids that organize into a dominant Ld phase. However,
as discussed below, vaccine antigens may adversely contribute to Ld
formation.
3.2. Antigen and NAb interactions with SLBs
On the POPC SLB (Ld), antigen presentation and NAb binding was
uniformly distributed across the entire SLB surface. This indicates that
the Ld phase does not restrict or hinder antibody/antigenmembrane in-
teractions and facilitates high antibody to antigen binding. In the POPC:
POPE:MPER656 SLB (gel-Ld), MPER656 resided exclusively in the Ld
phase. Gel domains not only excluded NAb interactions, but also
prevented MPER656 membrane integration. The presence of MPER656
also inhibited gel domain coalescence. This is seen in Fig. 3 where, in
presence of antigen, smaller gel domains still exist (Fig. 3E) when com-
pared to the gel domains in absence of antigen (Fig. 3A). However, the
overall Ld area remains relatively constant, i.e., 41 ± 4% without and
39 ± 2% with MPER656. The presence of MPER656 in the model HIV
SLB, decreased the total Ld area substantially. Without MPER656, the
model HIV SLB had an Ld coverage of 39 ± 3%, and with MPER656 the
Ld area decreased to 3±0%.When comparing themorphology between
the model HIV SLB without and with MPER656 (Fig. 4B vs. 4G), the
presence of antigen resulted in a more homogenous lipid phase that is
void of antigen–NAb binding. Large Ld areas fail to form, and the antigen
is likely limited to the location of small (~30–60 nm in diameter) Ld
pockets. This antigen distribution is in stark contrast to that in the
POPC:MPER656 (Fig. 2E) and POPC:POPE:MPER656 (Fig. 3E) SLBs,
where antigen is evenly distributed across the entire Ld phase. The
NAb binding coverage is the lowest in the model HIV:MPER656 SLB
(2 ± 0% for both 2F5 and 4E10) compared to that on POPC:MPER656
and POPC:POPE:MPER656 SLBs.
SPR experiments conﬁrmed that there is substantially less NAb–
MPER656 binding when MPER656 is included in the highly ordered
model HIV SLB when compared to the more ﬂuid POPC SLB. Since
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that the reduced NAb binding to the model HIV:MPER656 SLB arises
from the membrane structure and the organization of MPER656 in the
SLB. AFM topography images suggest that an ordered phase dominates
in the model HIV membrane (~97% surface coverage). Either this
ordered phase is completely void of MPER656 or the antigen is buried
in such an orientation that it cannot be detected by NAbs (or by the
AFM cantilever during imaging). AFM images also show that MPER656
appears to be restricted to the small pockets in the SLB that contain
the Ld phase (~3% surface coverage). Only a limited number of NAbs
can bind MPER656 in these areas (Fig. 4H,I), before steric restrictions
likely prevent unbound NAbs from accessing unbound antigens, thus
severely limiting NAb–antigen interactions.
4. Conclusions
Our results on SLBs demonstrate that NAbs 2F5/4E10 do not interact
with the highly ordered gel or Lo phase but exclusively bind to the Ld
phase. Using vaccine liposomes that mimic the high order of the HIV-1
envelope to induce antibodies that can recognize and bind to the viral
envelope, may, thus not be advantageous for 2F5/4E10 based vaccine
strategies. Rather, vaccine liposomes that contain an Ld phase may pro-
vide optimal selection of 2F5- and 4E10-like antibodies.
In the context of liposomal antigen presentation, our results suggest
that the presence of the MPER656 peptide may severely limit the Ld area
available for antibody interactions. Subsequently, this reduces the
amount of MPER656 that is accessible for 2F5/4E10 binding, since
MPER656 preferentially localizes to the Ld area. If Ld forming lipid com-
ponents are used in vaccine liposomes, it is important to ensure that
the presence of antigen does not inhibit large-scale Ld formation.
5. Materials and methods
5.1. Antibodies and antigen
Anti-HIV-1 gp41 (anti-membrane proximal) NAbs 4E10 and 2F5
were purchased from Polymun, Inc., Vienna, Austria. Mouse mAb
13H11 was produced from splenocytes from a mouse immunized with
HIV Env oligomer CON-S [32], as described.[33] SLBs containing embed-
ded HIV antigen, MPER656-GTH1 (CPC Scientiﬁc Inc., San Jose, CA) were
prepared by ﬁrst dissolving antigen in chloroform and then adding to
lipid mixture before being dried under nitrogen.
5.2. Lipid preparation
POPC, POPE, POPS, SM, and CH in chloroform (Avanti Polar Lipids,
Alabaster, Al) was brought to room temperature, dried under nitrogen,
and then dried under vacuum for three hours. The lipid ﬁlm was
reconstituted in 37 °C PBS without Ca2+ and Mg2+, pH 7.4 (Gibco
Invitrogen, Grand Island, NY), vortexed, sonicated, and extruded 11
times through a 0.4 μm ﬁlter (Whatman, Florham Park, NJ), and then
through a 0.1 μm ﬁlter [34]. The concentrated lipid solution was then
diluted to 0.4 mg/mL in PBS buffer and vortexed immediately before
use. After lipid extrusion, vesicle solutions were used within eight hours.
5.3. AFM imaging
The AFM images presented are the highest quality images that are
representative of the observations obtained from image replicates
(n = 3 for SLBs containing antibodies and n ≥ 4 for all other SLBs).
Unless otherwise noted, NAbs were added at approximately 4.7 μM for
SLBs without MPER656 and 2.0 μM for SLBs with MPER656. Control
antibody, 13H11 was added at 4.7 μM for all membranes tested. AFM
imaging was performed using a commercial AFM (Nanoscope IV,
Digital Instruments/Bruker, Santa Barbara, CA) operating at room
temperature. Images were obtained in buffer with tapping mode usingtriangular Si3N4 cantilevers (Bruker, SNL-10) with a spring constant of
0.06 N m−1. The formation of SLBs for AFM imaging was achieved by
α-helical (AH) peptide-induced vesicle fusion as previously described.
[22] Antibodies were added to SLB samples between AFM scans by
pipetting 20–50 μL of buffer containing antibodies to the water
meniscus on the mica sample. For experiments at 37 °C, a Thermal
Applications Controller (Bruker, Santa Barbara, CA) was used to heat
the sample. Percent coverage of lipid domains and bound antibodies
to SLB surfaces was calculated using height images analyzed with
ImageJ software. SLB RMS values (n = 4) were calculated with
NanoScope Analysis software.
5.4. Surface plasmon resonance
Surface plasmon resonance (SPR) measurements were performed
on a BIAcore 3000 (BIAcore Inc., Uppsala, Sweden) instrument. Anti-
body binding (100 ug/mL) was monitored in real-time at 25 °C with a
continuous ﬂow of PBS, pH 7.4 (Gibco Invitrogen, Grand Island, NY) at
20 μL/min for 2 min. For lipid surfaces, approximately 500 RU of lipo-
somes were captured on a BIAcore SPR L1 chip. BIAevaluation 3.0 soft-
ware (BIAcore Inc.) was used to determine Rmax values. A bivalent
analyte model was used to ﬁt the binding curves of 2F5/4E10-POPC:
MPER interactions and a Langmuir 1:1model was used to ﬁt the binding
curves of all other antibody-membrane interactions.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamem.2014.07.007.
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